UCBT remains viable option for patients without donor match

10/6/2008 | AABB

Experts say some 14,000 unrelated cord blood transplant procedures were done in the past decade, and the procedure remains a feasible option for patients who do not have a donor match. In hematopoietic stem cell transplant the focus continues to be cord blood, with Eurocord results showing 78% of children receiving UCBT with an HLA-identical or one-antigen mismatch graft surviving two years. St. Jude's Research Hospital focuses on most closely matched HLA types for haploidentical transplantation, followed by best mismatch for NK cell reactivity.

View Full Article in:

AABB

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT